Vanda Pharmaceuticals (VNDA) logo

Vanda Pharmaceuticals (VNDA) stock

$3.99
+1.01%

Medicines for sleep, worth $239MSmall-cap biotech

Quality Score
-4
Poor
In its industry
#188of 270
Checks firing
2of 14
Trending down
From 52-week high
-59.9%
under its best in a year

VNDA's Quality Score rose 2 points on Fri, Nov 13, to -4. It closed near its high of the day (2 chart checks started).

Follow VNDA's trial news. Pro members can get an alert when Vanda Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when VNDA files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextDec 12, 2026 · In 26 days“Quimilza TM BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026”FDA decision date · SEC filing · Oct 28
Cash$140M, about 4 quarters at the last year's spendingOn Sep 30 · the company says “through at least the end of 2027”

Key facts on VNDA

Key facts on VNDA
Since its Dec 2021 highDown 78% profit $33.2M → a $274.8M loss a year
Latest filing10-Q, Oct 29 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026
1 more reason behind VNDA's -4, free with an account →5 more reasons behind VNDA's -4, for Pro members.

VNDA in the news

Big story

Tue Oct 27: Trial

Vanda reports positive trial results for GLP-1 vomiting drug By Investing.com

VNDA closed +1.3% that day on 2.0x normal volume.

Reported by investing.com uk · covered by 5 outlets

Get an alert on VNDA's next big story →

Outlet counts from the GDELT Project. The move is what VNDA did that session, not a claim about why.

What's next

Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.

Expected to report Wed Feb 17, after the close

After its last 4 reports it closed -7.5% on average, higher 2 of 4 times.

1 more date ahead: the conference, for Pro members.

Cash$140M, about 4 quarters at the last year's spendingOn Sep 30 · the company says “through at least the end of 2027”

VNDA catalysts

Coming up

4 more coming up and 11 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for VNDA, and how long its cash lasts

Next step the company has named

Dec 12In 26 days“Quimilza TM BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026”FDA decision date · SEC filing · Oct 28

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

A trial underway
Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderPhase 3 · Active · 500 people · main data estimated Dec 2026 · NCT07221578

15 more trials, 1 with data due this year, 2 more milestones and 47 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 4 quarters

$140M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “through at least the end of 2027” (8-K, Aug 5).

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Feb 12, 2026)
  • At-the-market share sales program (S-3, filed Feb 12, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director Charles Cliff Duncan bought 10,000 shares on Nov 5. 6 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Mihael Polymeropoulos’s 13 filings and quotes.

Get an alert before VNDA's FDA date

A free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

Why VNDA scores -4

Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

  • +2Chart checks 2 of 14 firing right now, one point each
  • −3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
  • Size subtracts
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
  • Insider trades adds

No effect today: Run-up, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on VNDA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 5:03 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when VNDA's Quality Score turns up

A free account. No card.Pro, 7 days free with a card.

How VNDA ranks in Biotech

VNDA is #188 of 270 by Quality Score.

How VNDA ranks in Biotech
RankStockQuality Score
188Vanda Pharmaceuticals (VNDA) logoVNDAVanda Pharmaceuticals-4

Share count against a year before: VNDA +2.3%, MLYS +26%.

More in Biotech

When does VNDA report earnings, and what happens after?

Expected to report Wed Feb 17, after the close (in 93 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What VNDA reported on Oct 28, 2026

The quarter

Sales of $69.8M, 24% more than a year ago; a loss of $0.37 a share, from $0.38.

“We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Fanaptup 24%$38.8M56%$36M71%$31.2M56%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 29)

3 more lines, for Pro members.

The outlook

The outlook the company gave, by period
MeasureFigure
Full year 2026
Total revenuegreater than $240 million

Figures as filed (SEC filing, Oct 28)

In the company's words

  • “As certain of these activities began concluding in Q3 2026, operating expenses have decreased and Vanda expects operating expenses to decrease further in future quarters, as the remainder of these activities conclude.”

From its results filing (SEC filing · Oct 28)

The numbers

Market value
$239M
today
Sales
$229M
up 8.1% on the year
Free cash flow
-$140M
last 12 months

Sales fell 2.7% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 1.3% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on VNDA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-14.1%+0.5%+1.3%
May 6Aug 5Oct 28
ReportedGapReaction5
days
Oct 28, 2026After close+11.4%+1.3%-3.0%
Aug 5, 2026After close-8.8%+0.5%+2.0%
May 6, 2026After close-5.7%-14.1%-13.6%

VNDA closed higher after 2 of its last 4 reports.

All 4 reports, and VNDA's Quality Score going into each

VNDA sales and profit by year

Sales and profit by year

Sales grew in five of the last seven years, to $216M in 2025. It made a profit in six of the eight years.

VNDA has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on VNDA, and all 14 on every stock.Get in free →

VNDA RSI on Nov 13: 45.4, below its 50-day and 200-day averages

Not scored

RSI 45.4, MACD above signal, below both averages. Not scored.

The deep dive on VNDA

  • What it does and how it makes money7 findings"We are also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that we receive from a third party in connection with any sublicensing arrangement, at a rate which is in the mid-twenties." (10-K for fiscal 2025)SEC filing · Feb 12, 2026"We have filed additional patent applications based on discoveries made during recent studies with NEREUS TM , the latest of which expires in 2036." (10-K for fiscal 2025)SEC filing · Feb 12, 2026
  • Where it stands2 findingsFor Pro members2 findings on where VNDA stands: its cash, debt, and share count, for Pro members
  • What changed in its filings11 findings"In response, in July 2026, the Company filed a patent infringement action against Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. (collectively, Alembic) in the Delaware District Court." (10-Q for the quarter to Sep 30, 2026)SEC filing · Oct 29, 2026A new heading in its "Risk Factors" this year: "We might not obtain the necessary regulatory approvals to commercialize current product candidates, including Bysanti TM and imsidolimab." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 12, 2026, against the one of Feb 14, 2025One customer made up 76% of its revenue in fiscal 2025, up from 69% in fiscal 2024; another made up 25%, up from 17% in fiscal 2024.SEC filing · Feb 12, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades VNDA, for Pro members
  • Against its closest peers1 peerShare count against a year before: VNDA +2.3%, MLYS +26%.

17 more findings on VNDA, each with its source, for Pro members.

VNDA share count over time

2% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of VNDA outstanding, as filed
Shares
outstanding
As
of
60.5MOct 22, 2026
60.5MJul 30, 2026
60.1MApr 30, 2026
59.1MFeb 5, 2026
Offerings, shelves, and splits of VNDA, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3)Feb 12, 2026

VNDA insider trades

One insider bought $38K across 3 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyCharles Cliff Duncan$22KDirectorat $3.80 on Nov 5, filed Nov 5

All 3 insider filings on VNDA from the last six months, for Pro members.

All VNDA insider trades

VNDA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

4 more officers and directors file at VNDA.

See insider trades by person

Which ETFs hold VNDA?

In ETFs: VNDA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

533 employeesWashington, DCvandapharma.com

What Vanda Pharmaceuticals says it competes with

“The pharmaceutical industry, in particular, is highly competitive and includes a number of established large and mid-sized companies with greater financial, technical and personnel resources than we have and significantly greater commercial infrastructures than we have.”

From its annual report, SEC filing · Feb 12, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on VNDA and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn VNDA's score around: 8 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayNov 5Charles Cliff Duncan bought VNDA$22K at $3.80, filed Nov 5

Alerts are optional.

See VNDA's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: VNDA's Quality Score is -4 (Poor), #188 of 270 in Biotech. Insiders bought $38K in the last 6 months (Form 4).

What does VNDA's Quality Score say?

VNDA scores -4 today, which Breakaway calls Poor. It is #188 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is VNDA's Quality Score?

VNDA scores -4 today, which Breakaway calls Poor (below zero). That is #188 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VNDA's -4.

Are insiders buying VNDA?

One insider bought $38K across 3 filings in the last 6 months. No open-⁠market sales on record. The newest is Charles Cliff Duncan, Director, who bought $22K on Nov 5. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for Vanda Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.